Experience gained conducting numerous clinical trials with alcoholics has provided the infrastructure and knowledge for us to address novel treatments in a scientifically vigorous manner. In particular, we have found naltrexone to be efficacious when combined with cognitive behavioral therapy (CBT) and are currently investigating its efficacy when combined with either CBT or motivational enhancement therapy. In both studies, comprising over 250 individuals, most relapse occurs during early treatment (during the first six weeks) during which individuals complain of sleep difficulty, irritability and nervousness. These symptoms are indicative of brain dysregulation and may be related to """"""""protracted alcohol withdrawal"""""""". Gabapentin, a safe and effective FDA approved antiseizure compound used in millions of individuals worldwide, can reduce glutamate and increase GABA neurotransmission in the brain. This unique pharmacology is well suited to the treatment of alcohol withdrawal and could normalize the brain dysregulation seen during the early abstinence period. A number of pre-clinical and clinical studies at our Center have indicated that it can reduce alcohol withdrawal symptoms, reduce drinking in dependent animals, and is safe to use in the clinic. We purpose a randomized double blind clinical trial, to evaluate the adjunctive use of gabapentin with naltrexone for the treatment of alcohol dependent individuals using a three group (placebo alone, placebo plus naltrexone, gabapentin plus naltrexone) design. Gabapentin or placebo will be added to naltrexone for the first six weeks of treatment (the time of greatest relapse and of potential 'protracted withdrawal"""""""" symptoms). Naltrexone and/or placebo treatment will last 16 weeks and all subjects will receive Combined Behavioral Intervention as developed for the COMBINE study (in which we are participating). It is predicted that alcoholics receiving naltrexone and adjunctive gabapentin will have less relapse than those treated with naltrexone alone. Measures of mood, sleep, irritability, and anxiety will be compared between treatment groups. Evaluations occur during treatment and 12 weeks and 24 weeks post-treatment. This evaluation of a novel treatment will allow us to better understand combined pharmacotherapy and develop a new paradigm for medications development for alcoholism.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Research Project (R01)
Project #
5R01AA009568-15
Application #
7114915
Study Section
Health Services Research Review Subcommittee (AA)
Program Officer
Fertig, Joanne
Project Start
1992-09-30
Project End
2009-08-31
Budget Start
2006-09-01
Budget End
2009-08-31
Support Year
15
Fiscal Year
2006
Total Cost
$454,568
Indirect Cost
Name
Medical University of South Carolina
Department
Psychiatry
Type
Schools of Medicine
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29425
Adams, Zachary W; Schacht, Joseph P; Randall, Patrick et al. (2016) The Reasons for Heavy Drinking Questionnaire: Factor Structure and Validity in Alcohol-Dependent Adults Involved in Clinical Trials. J Stud Alcohol Drugs 77:354-61
Anton, Raymond F; Myrick, Hugh; Wright, Tara M et al. (2011) Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry 168:709-17
Baros, A M; Wright, T M; Latham, P K et al. (2008) Alcohol consumption, %CDT, GGT and blood pressure change during alcohol treatment. Alcohol Alcohol 43:192-7
Baros, A M; Latham, P K; Anton, R F (2008) Naltrexone and cognitive behavioral therapy for the treatment of alcohol dependence: do sex differences exist? Alcohol Clin Exp Res 32:771-6
Baros, Alicia M; Latham, Patricia K; Moak, Darlene H et al. (2007) What role does measuring medication compliance play in evaluating the efficacy of naltrexone? Alcohol Clin Exp Res 31:596-603
Anton, Raymond F; Moak, Darlene H; Latham, Patricia et al. (2005) Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol 25:349-57
Anton, R F (2001) Pharmacologic approaches to the management of alcoholism. J Clin Psychiatry 62 Suppl 20:11-7
Anton, R F (2001) Carbohydrate-deficient transferrin for detection and monitoring of sustained heavy drinking. What have we learned? Where do we go from here? Alcohol 25:185-8
Anton, R F (2000) Obsessive-compulsive aspects of craving: development of the Obsessive Compulsive Drinking Scale. Addiction 95 Suppl 2:S211-7
Horner, M D; Waid, L R; Johnson, D E et al. (1999) The relationship of cognitive functioning to amount of recent and lifetime alcohol consumption in outpatient alcoholics. Addict Behav 24:449-53

Showing the most recent 10 out of 21 publications